S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma

Thomas Elmer Witzig, Thomas Matthew Habermann, P. J. Kurtin, G. Schroeder, M. J. Stenson, P. R. Greipp

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Background. The purpose of this study was to learn if the bromodeoxyuridine labeling index (LI), a measure of the S-phase fraction, is an independent prognostic factor for overall survival (OS) for patients with newly diagnosed low grade non-Hodgkin's lymphoma (NHL). In addition, the ability of the LI to predict time to progression (TTP) in a group of patients observed without therapy after initial diagnosis was determined. Methods. Patients eligible for this study had biopsy proven low grade NHL, adequate tissue to perform the LI, and were previously untreated. The bromodeoxyuridine LI was performed on fresh biopsy samples using a slide- based immunofluorescence procedure. Results. One-hundred twelve patients were followed prospectively for OS, and 50 of these patients who initially were observed without therapy were eligible for an analysis of TTP. The LI (≤1% vs. >1%) and presence of 'B' symptoms were significant univariate prognostic factors for survival (P values of 0.004 and <0.001, respectively). In a multivariate analysis, the LI and symptoms retained independent prognostic significance, whereas disease stage, histologic subtype, and age did not. In the group who were observed after diagnosis, the LI was not an independent predictor of TTP. Conclusions. The LI at initial diagnosis is an independent prognostic factor for OS of patients with low grade NHL, but it does not help choose patients for observation without therapy. Measurements of the LI should be considered as part of the on-study evaluation of patients entering cooperative group trials evaluating new therapies for this group of lymphomas.

Original languageEnglish (US)
Pages (from-to)1059-1064
Number of pages6
JournalCancer
Volume76
Issue number6
DOIs
StatePublished - 1995

Fingerprint

S Phase
Non-Hodgkin's Lymphoma
Survival
Bromodeoxyuridine
Biopsy
Aptitude
Group Psychotherapy
Fluorescent Antibody Technique
Lymphoma
Therapeutics
Multivariate Analysis
Observation

Keywords

  • cell kinetics
  • cell proliferation
  • labeling index
  • non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma. / Witzig, Thomas Elmer; Habermann, Thomas Matthew; Kurtin, P. J.; Schroeder, G.; Stenson, M. J.; Greipp, P. R.

In: Cancer, Vol. 76, No. 6, 1995, p. 1059-1064.

Research output: Contribution to journalArticle

@article{972f6ad5e0584fa79b828a4c350cb7f1,
title = "S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma",
abstract = "Background. The purpose of this study was to learn if the bromodeoxyuridine labeling index (LI), a measure of the S-phase fraction, is an independent prognostic factor for overall survival (OS) for patients with newly diagnosed low grade non-Hodgkin's lymphoma (NHL). In addition, the ability of the LI to predict time to progression (TTP) in a group of patients observed without therapy after initial diagnosis was determined. Methods. Patients eligible for this study had biopsy proven low grade NHL, adequate tissue to perform the LI, and were previously untreated. The bromodeoxyuridine LI was performed on fresh biopsy samples using a slide- based immunofluorescence procedure. Results. One-hundred twelve patients were followed prospectively for OS, and 50 of these patients who initially were observed without therapy were eligible for an analysis of TTP. The LI (≤1{\%} vs. >1{\%}) and presence of 'B' symptoms were significant univariate prognostic factors for survival (P values of 0.004 and <0.001, respectively). In a multivariate analysis, the LI and symptoms retained independent prognostic significance, whereas disease stage, histologic subtype, and age did not. In the group who were observed after diagnosis, the LI was not an independent predictor of TTP. Conclusions. The LI at initial diagnosis is an independent prognostic factor for OS of patients with low grade NHL, but it does not help choose patients for observation without therapy. Measurements of the LI should be considered as part of the on-study evaluation of patients entering cooperative group trials evaluating new therapies for this group of lymphomas.",
keywords = "cell kinetics, cell proliferation, labeling index, non-Hodgkin's lymphoma",
author = "Witzig, {Thomas Elmer} and Habermann, {Thomas Matthew} and Kurtin, {P. J.} and G. Schroeder and Stenson, {M. J.} and Greipp, {P. R.}",
year = "1995",
doi = "10.1002/1097-0142(19950915)76:6<1059::AID-CNCR2820760621>3.0.CO;2-E",
language = "English (US)",
volume = "76",
pages = "1059--1064",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - S-phase fraction by the labeling index as a predictive factor for progression and survival in low grade non-Hodgkin's lymphoma

AU - Witzig, Thomas Elmer

AU - Habermann, Thomas Matthew

AU - Kurtin, P. J.

AU - Schroeder, G.

AU - Stenson, M. J.

AU - Greipp, P. R.

PY - 1995

Y1 - 1995

N2 - Background. The purpose of this study was to learn if the bromodeoxyuridine labeling index (LI), a measure of the S-phase fraction, is an independent prognostic factor for overall survival (OS) for patients with newly diagnosed low grade non-Hodgkin's lymphoma (NHL). In addition, the ability of the LI to predict time to progression (TTP) in a group of patients observed without therapy after initial diagnosis was determined. Methods. Patients eligible for this study had biopsy proven low grade NHL, adequate tissue to perform the LI, and were previously untreated. The bromodeoxyuridine LI was performed on fresh biopsy samples using a slide- based immunofluorescence procedure. Results. One-hundred twelve patients were followed prospectively for OS, and 50 of these patients who initially were observed without therapy were eligible for an analysis of TTP. The LI (≤1% vs. >1%) and presence of 'B' symptoms were significant univariate prognostic factors for survival (P values of 0.004 and <0.001, respectively). In a multivariate analysis, the LI and symptoms retained independent prognostic significance, whereas disease stage, histologic subtype, and age did not. In the group who were observed after diagnosis, the LI was not an independent predictor of TTP. Conclusions. The LI at initial diagnosis is an independent prognostic factor for OS of patients with low grade NHL, but it does not help choose patients for observation without therapy. Measurements of the LI should be considered as part of the on-study evaluation of patients entering cooperative group trials evaluating new therapies for this group of lymphomas.

AB - Background. The purpose of this study was to learn if the bromodeoxyuridine labeling index (LI), a measure of the S-phase fraction, is an independent prognostic factor for overall survival (OS) for patients with newly diagnosed low grade non-Hodgkin's lymphoma (NHL). In addition, the ability of the LI to predict time to progression (TTP) in a group of patients observed without therapy after initial diagnosis was determined. Methods. Patients eligible for this study had biopsy proven low grade NHL, adequate tissue to perform the LI, and were previously untreated. The bromodeoxyuridine LI was performed on fresh biopsy samples using a slide- based immunofluorescence procedure. Results. One-hundred twelve patients were followed prospectively for OS, and 50 of these patients who initially were observed without therapy were eligible for an analysis of TTP. The LI (≤1% vs. >1%) and presence of 'B' symptoms were significant univariate prognostic factors for survival (P values of 0.004 and <0.001, respectively). In a multivariate analysis, the LI and symptoms retained independent prognostic significance, whereas disease stage, histologic subtype, and age did not. In the group who were observed after diagnosis, the LI was not an independent predictor of TTP. Conclusions. The LI at initial diagnosis is an independent prognostic factor for OS of patients with low grade NHL, but it does not help choose patients for observation without therapy. Measurements of the LI should be considered as part of the on-study evaluation of patients entering cooperative group trials evaluating new therapies for this group of lymphomas.

KW - cell kinetics

KW - cell proliferation

KW - labeling index

KW - non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0029126907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029126907&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950915)76:6<1059::AID-CNCR2820760621>3.0.CO;2-E

DO - 10.1002/1097-0142(19950915)76:6<1059::AID-CNCR2820760621>3.0.CO;2-E

M3 - Article

C2 - 8625208

AN - SCOPUS:0029126907

VL - 76

SP - 1059

EP - 1064

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -